Gilead's Yeztugo Sees Growth Amid Insurance Barriers

Key Developments

Gilead Sciences' twice-yearly HIV prevention injection, Yeztugo, is experiencing increased adoption since its launch. However, significant hurdles related to U.S. insurance coverage and patient preference are tempering its market penetration, despite its near-100% effectiveness in clinical trials.

Market Landscape

In the first quarter, over 9,000 prescriptions for Yeztugo were filled, a fraction of the 461,000 for Gilead's daily pill, Descovy. The high list price of over $14,000 per shot and its classification as a medical benefit by many insurers lead to patient cost-sharing, unlike older, low-cost generic PrEP options.

Economic and Insurer Impact

Major insurers report that Yeztugo's post-discount price remains substantially higher than alternatives. This cost difference, combined with a lack of updated federal preventive care guidelines that would mandate zero-cost coverage, creates reimbursement challenges for providers and access barriers for patients.

Summary and Outlook

Analysts project Yeztugo sales could exceed $5 billion annually by 2032. Achieving this target will depend on Gilead's ability to navigate complex insurance reimbursement systems and demonstrate a clear value proposition over established daily pills for a wider patient base.

FAQ

Q: Why is Yeztugo facing insurance issues?
A: It is often treated as a medical benefit subject to co-pays and is not yet included in federal guidelines that mandate free preventive HIV medication.

Q: How does Yeztugo's uptake compare to other PrEP options?
A: Its Q1 prescription volume of over 9,000 is growing but remains significantly lower than the 461,000 for the market-leading daily pill, Descovy.

Source: investing.com